We are live on
!
Find out more
Syndax Pharmaceuticals
SNDX
SNDX
136 hedge funds and large institutions have $943M invested in Syndax Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 53 increasing their positions, 31 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
7,305% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $21K
71% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 31
17% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 23
3% more funds holding
Funds holding: 132 → 136 (+4)
0.59% less ownership
Funds ownership: 99.77% → 99.19% (-0.59%)
18% less capital invested
Capital invested by funds: $1.15B → $943M (-$203M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Holders
136
Holders Change
+4
Holders Change %
+3.03%
% of All Funds
2.15%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
27
Increased
53
Reduced
31
Closed
23
Calls
$1.55M
Puts
$21K
Net Calls
+$1.53M
Net Calls Change
-$3.41M
Top Buyers
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$16.4M |
| 2 |
Morgan Stanley
New York
|
+$7.08M |
| 3 |
Millennium Management
New York
|
+$6.86M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$4.97M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$4.18M |
